Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA

Scholar Rock Holding Corp. (SRRK) Prices 2.949M Share Common Offering at $39/Sh; Prices 2.18M Prefunded Warrants at $38.99/Warrant

October 29, 2020 5:59 AM EDT

Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an underwritten public offering of 2,948,718 shares of its common stock at a public offering price of $39.00 per share. In addition, in lieu of common stock to certain investors, Scholar Rock is offering pre-funded warrants... More

Scholar Rock (SRRK) PT Raised to $52 at BMO Capital

October 27, 2020 3:39 PM EDT

BMO Capital analyst Do Kim raised the price target on Scholar Rock (NASDAQ: SRRK) to $52.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented, "We raise our SRK-015 estimates and target price to $52 from $33, as our probability of success increase to 50% from 33%, following... More